Latest revenue
$104.8M
as of 2026-03-31
Latest net income
$-11.8M
as of 2026-03-31
Net margin
-11.3%
as of 2026-03-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Surgical & Medical Instruments & Apparatus (138 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 7, 2026.
Community sentiment
Where do you think ARAY is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $40.7M
- Enterprise value
- $160.7M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 0.98×
- Dividend yield
- 0.0%
- 52-wk high
- $2.10
- 52-wk low
- $0.25
- Beta
- —
- Shares out
- 119.0M
5-year trend
What this company does
Item 1. BUSINESS The Company Accuray Incorporated is a radiation therapy company that develops, manufactures, sells and supports market-changing solutions that are designed to deliver radiation treatments for even the most complex cases, while making commonly treatable cases even more straightforward, to meet the full spectrum of patient needs. We believe in comparison to conventional linear accelerators, our treatment delivery, planning, and data management solutions provide better accuracy, flexibility, and control; fewer treatments with shorter treatment times; and the technology to expand beyond cancer, making it easier for clinical teams around the world to provide treatments that help…
AI summary unavailable — showing raw filing excerpt
Generated from ARAY's filing dated 2025-08-28
Key risks
Item 1A. RISK FACTORS Risk Factors Summary Our business is subject to numerous risks and uncertainties, including those highlighted in Part I, Item 1A titled “Risk Factors.” These risks include, but are not limited to, the following: Risks related to our business and results of operations •We face risks related to the current global economic environment, which could adversely affect our business, financial condition and results of operations. •If our products do not achieve widespread market acceptance, we will not be able to generate the revenue necessary to support our business. •Our ability to achieve profitability depends in part on maintaining or increasing our gross margins on product…
AI summary unavailable — showing raw filing excerpt
Generated from ARAY's filing dated 2025-08-28
Profitability
Gross margin
32.1%
0.1%Operating margin
1.7%
1414.8%Net margin
-0.3%
90.0%Return on equity
-3.5%
87.8%Return on assets
-0.3%
89.8%Leverage
Debt / equity
9.43×
21.9%Long-term debt / equity
2.75×
10.4%Debt / assets
90.4%
2.1%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $104.8M | -7.4% | $-11.8M | -810.2% | -11.3% |
Q4 2025 2025-12-31 | $102.2M | -12.0% | $-13.8M | -871.8% | -13.5% |
Q3 2025 2025-09-30 | $93.9M | -7.5% | $-21.7M | -448.3% | -23.1% |
Q2 2025 2025-06-30 | $127.5M | -5.0% | $5.1M | +49.9% | 4.0% |
Q1 2025 2025-03-31 | $113.2M | +12.0% | $-1.3M | +79.5% | -1.1% |
Q4 2024 2024-12-31 | $116.2M | +8.3% | $-1.4M | +85.3% | -1.2% |
Q3 2024 2024-09-30 | $101.5M | -2.3% | $-4.0M | -33.2% | -3.9% |
Q2 2024 2024-06-30 | $134.3M | — | $3.4M | — | 2.5% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Surgical & Medical Instruments & Apparatus · SIC 3841
Your notes
Keep private notes on ARAY — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$216.4K
Insider selling
$0
Net activity
+$216.4K
Distinct insiders
3
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns ARAY
Institutional value
$11.5M
Total shares held
30.4M
Distinct holders
69
-55 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 8.5M | $3.3M | -88.7K (-1.0%) | Trimmed |
| 2 | WEBER CAPITAL MANAGEMENT LLC /ADV | 5.1M | $2.0M | +0 (+0.0%) | No change |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 4.4M | $1.7M | — | New |
| 4 | MACKENZIE FINANCIAL CORP | 2.3M | $910.6K | +428.3K (+22.3%) | Added |
| 5 | HEARTLAND ADVISORS INC | 2.0M | $767.4K | -1.4M (-40.6%) | Trimmed |
| 6 | UBS Group AG | 1.4M | $543.9K | +1.0M (+283.5%) | Added |
| 7 | VANGUARD FIDUCIARY TRUST CO | 765.4K | $297.0K | — | New |
| 8 | Kovack Advisors, Inc. | 738.1K | $287.0K | -1.2M (-61.3%) | Trimmed |
| 9 | Silverberg Bernstein Capital Management LLC | 655.7K | $254.5K | +7.1K (+1.1%) | Added |
| 10 | VANGUARD PORTFOLIO MANAGEMENT LLC | 595.2K | $230.9K | — | New |
| 11 | Mitsubishi UFJ Asset Management Co., Ltd. | 334.0K | $129.6K | +50.4K (+17.8%) | Added |
| 12 | Invesco Ltd. | 328.2K | $127.4K | +83.2K (+33.9%) | Added |
| 13 | Nuveen, LLC | 295.4K | $114.6K | +1.7K (+0.6%) | Added |
| 14 | DIMENSIONAL FUND ADVISORS LP | 294.9K | $114.2K | -60 (-0.0%) | Trimmed |
| 15 | DEUTSCHE BANK AG\ | 245.1K | $95.6K | +156.6K (+176.8%) | Added |
| 16 | Bank of New York Mellon Corp | 220.0K | $85.4K | +0 (+0.0%) | No change |
| 17 | Assenagon Asset Management S.A. | 204.0K | $79.2K | -1.2K (-0.6%) | Trimmed |
| 18 | Williams & Novak, LLC | 182.0K | $70.8K | +63.2K (+53.2%) | Added |
| 19 | North Star Investment Management Corp. | 164.6K | $63.9K | -519.7K (-75.9%) | Trimmed |
| 20 | WELLS FARGO & COMPANY/MN | 147.5K | $57.3K | -72.5K (-32.9%) | Trimmed |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once ARAY's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.